Litcius/Paper detail

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

Delvys Rodríguez‐Abreu, Steven Powell, Maximilian J. Hochmair, Shirish M. Gadgeel, Emilio Esteban, Enriqueta Felip, G. Speranza, F. De Angelis, Manuel Dómine, Susanna Y. Cheng, Helge Bischoff, Nir Peled, Martin Reck, Rita L. Hui, Edward B. Garon, Michael Boyer, Takayasu Kurata, Jing Yang, M. Catherine Pietanza, Francis Ribeiro de Souza, Marina Chiara Garassino

2021Annals of Oncology418 citationsDOIOpen Access PDF

Topics & Concepts

PemetrexedPembrolizumabMedicineCarboplatinInternal medicineOncologyLung cancerHazard ratioPlaceboChemotherapyProgression-free survivalCisplatinConfidence intervalCancerPathologyImmunotherapyAlternative medicineCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 | Litcius